Report of Foreign Issuer (6-k)

---

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2017

Commission file number: 001-36621

FOAMIX PHARMACEUTICALS LTD.

(Translation of registrant's name into English)

2 Holzman Street, Weizmann Science Park

Rehovot, Israel
(Address of principal executive office)

_____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   

 

Form 20-F S            Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): £

 

CONTENTS

This report on Form 6-K of the registrant consists of (i) a press release issued by the registrant on March 27, 2017, and (ii) a presentation dated March 2017, each of which is attached hereto as an exhibit and incorporated by reference herein.

The information contained in this Form 6-K is incorporated by reference into (i) the registration statement on Form S-8 (number 333-199486) of the registrant, filed with the Securities and Exchange Commission (the "SEC"), as amended by the post-effective registration statement on Form S-8 POS filed February 5, 2016, (ii) the registration statement on Form S-8 (number 333-209403) of the registrant, filed with the SEC, and (iii) the registration statement on Form F-3 (333-216224) of the registrant, filed with the SEC on February 24, 2017, in each case to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits

99.1	Press release: Foamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
99.2	Presentation: FMX101 Topical 4% Minocycline Foam for Moderate-to-Severe Acne – Phase 3 Results

---

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FOAMIX PHARMACEUTICALS  LTD. (Registrant)
	By:	/s/ Ilan Hadar
		Name: Ilan Hadar
		Title:   Chief Financial Officer

Date: March 27, 2017

 

2

---